Natural Course of Congenital Hydronephrosis in Infants Aged 0-6 Months

NCT07382570 · tracked via the Priya Life Science China tracker

Sponsor

The Children's Hospital of Zhejiang University School of Medicine

Phase

Observational

Started

2026-03-01

Last updated

2026-02-11

Condition(s) studied

Congenital HydronephrosisUTD Grading SystemNatural ProgressionPediatric

Investigational drug(s) / intervention(s)

No Intervention: Observational Cohort

No Intervention: Observational Cohort: No intervention

Study summary

This project aims to systematically delineate the natural progression of congenital hydronephrosis diagnosed within the critical window of 0-6 months through a prospective, multicenter, observational cohort study. The focus will be on analyzing the resolution rates, progression rates, and influencing factors of hydronephrosis of varying severities based on the UTD grading system.

Congenital hydronephrosis is one of the most common congenital urinary system abnormalities in children, with a high prenatal detection rate. However, its postnatal natural course is highly heterogeneous, leading to significant controversy in clinical management regarding follow-up intensity and intervention timing. Currently, there is a lack of prospective, large-sample, multicenter natural history data in China. By establishing a standardized follow-up system and collecting high-quality clinical and imaging data, this study aims to provide high-level evidence-based medical support for developing individualized and precise clinical management strategies, thereby reducing unnecessary interventions and delayed treatment. Consequently, conducting this multicenter study holds significant clinical and scientific value.

Eligibility

Sex

ALL

Min age

0 Months

Max age

6 Months

Healthy volunteers

Inclusion Criteria: * Diagnostic Criteria: Congenital hydronephrosis is diagnosed by abdominal ultrasound examination and meets the UTD grading system criteria (Grades I-III). This is defined as an anterior-posterior renal pelvis diameter (APD) ≥4 mm during the fetal period or ≥7 mm after birth, or accompanied by calyceal dilation, renal parenchymal changes, and other manifestations. * Informed Consent: The legal guardian voluntarily agrees to participate in the study and provides written informed consent. * Follow-up Feasibility: The guardian commits to cooperating with the complete 3-year follow-up period, including attending regular examinations at the research center, and maintains stable contact information. Exclusion Criteria: * Presence of other severe congenital malformations that may affect follow-up or prognosis assessment, such as congenital heart disease, biliary atresia, spina bifida, etc. * Secondary hydronephrosis caused by acquired factors (e.g., urinary system tumors, stones, trauma) or well-defined genetic metabolic diseases. * Having received interventional treatments prior to enrollment, such as surgical procedures related to hydronephrosis (e.g., pyeloplasty) or pharmacological interventions (e.g., long-term use of diuretics). * Severe underlying diseases that preclude tolerance for long-term follow-up, such as severe infections, respiratory failure, or renal failure (e.g., glomerular filtration rate \< 30 ml/min/1.73m²). * Inability of the legal guardian to cooperate due to mental illness, cognitive impairment, or refusal to comply with follow-up schedules and data collection requirements.

Primary outcome measure(s)

Hydronephrosis Resolution Rate — During the follow-up period (3 years)
During the follow-up period (3 years), the child's hydronephrosis decreased from the UTD grade at enrollment to grade I or below, and this status persisted for ≥6 months.

Trial sites (1)

Facility	City	Region	Status
Children's hospital, Zhejiang Univeristy School of Medicine	Hangzhou	Zhejiang

More The Children's Hospital of Zhejiang University School of Medicine trials in China

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE Recruiting

Clinical Effectiveness of Non-contact Heart Rate and Respiratory Rate Monitoring System Active, not recruiting

Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML Active, not recruiting

Exergame-Based Physical Activity Promotion for Children and Adolescents With Congenital Heart Disease Starting soon

Construction and Validation of an Intelligent Ultrasound Diagnostic System for the Spectrum of Neuroblastoma in Children Active, not recruiting

Other trials for the same condition

The ED95 of Ciprofol for Laryngeal Mask Airway Insertion With Fentanyl in Children: A Biased-Coin Dose-Finding Trial Recruiting

Remimazolam and Emergence Delirium in Pediatrics Recruiting

The Roles of Human Microbiome and Vitamin D in the Development of Childhood Allergic Diseases Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07382570 on ClinicalTrials.gov ↗ ← All trials in China